Thermo Fisher Scientific JIP3 Polyclonal Antibody

Applications and Tested Dilution

Product Specifications

Target Information

c-Jun NH2-terminal kinases (JNKs) are distant members of the MAP kinase family.
JNK1 is activated by dual phosphorylation at a Thr-Pro-Tyr motif in response to ultraviolet (UV) light and functions to phosphorylate c-Jun at amino terminal serine regulatory sites Ser 63 and Ser 73, resulting in transcriptional activation.
Two additional JNK family members, JNK2 and JNK3, have been identified.

JIP-1 (JNK interacting protein-1) acts as a cytoplasmic inhibitor of JNK, retaining JNK in the cytoplasm and inhibiting JNK-regulated gene expression.
Evidence suggests that JNK1 and JNK2 bind to JIP-1 with greater affinity than to ATF-2 and c-Jun, which are targets of the JNK signaling pathway.
JIP-1 contains an amino terminal JNK binding domain and a carboxy terminal SH3 domain.
ATF-2 and c-Jun also contain the JNK binding domain and are thought to compete with JIP-1 for JNK binding.
Multiple splice variants of JIP-1, including JIP-1b, JIP-1c (also designated islet-brain 1 or IB-1), JIP-2a, JIP-2b, and JIP-3, have been identified in brain.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.